Zealand Pharma A/S

299 articles about Zealand Pharma A/S

• Positive Phase I Data for Zealand Pharma 's ZP1848 in Crohn's Disease

  10/15/2010

• Sanofi-Aventis (France) Announce Partner Zealand Pharma Has Positive Study Findings from Lixisenatide in First Phase III Get Goal Trial for Type 2 Diabetes

  9/20/2010

• Zealand Pharma Announces An Extension Of The Lixisenatide Global Licensing Agreement With Sanofi-Aventis K.K. For Type-2 Diabetes

  6/8/2010

• Zealand Pharma : Annual Review for 2009

  5/6/2010

• Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma 's Partner Sanofi-Aventis (France)

  4/15/2010

• Zealand Pharma Announces Augmentation of its Management Team as it Continues its Growth Strategy

  3/8/2010

• Sanofi-Aventis (France) May Take Stake in Zealand Pharma for up to $143 Million

  12/23/2009

• Zealand Pharma Advances A New Generation Of Type 2 Diabetes Treatment

  9/1/2009

• Vyteris, Inc. and Zealand Pharma Announce Agreement on Active Transdermal Patch for Peptide Drugs

  4/14/2009

• Vyteris, Inc. and Zealand Pharma Announce Agreement on Active Transdermal Patch for Peptide Drugs

  4/14/2009

• Zealand Pharma Receives Frost & Sullivan 2008 European Research & Development Award

  3/18/2009

• Helsinn Healthcare SA Announces Partnering Agreement for ZP1846, a Novel GLP-2 Agonist from Zealand Pharma

  12/11/2008

• Zealand Pharma and Helsinn Healthcare SA Sign a €140 Million (US$176.8 Million) Partnering Agreement for ZP1846, a Novel GLP-2 Agonist

  12/2/2008

• Zealand Pharma Appoints New Chief Executive Officer

  8/28/2008

• Phase III Program for AVE0010/ZP10 Licensed From Sanofi-Aventis (France) will Begin in the First Quarter of 2008

  2/12/2008

• Wyeth and Zealand Pharma Advance the First Orally Available Gap Junction Modifier into Phase I Clinical Trials

  10/10/2007

• FDA Has Approved Zealand Pharma 's Investigative New Drug Application (IND) for ZP1846 to Be Administered in Humans; ZP1846 Is Developed for the Prevention and Treatment of Severe Diarrhoea Induced by Chemotherapy

  9/6/2007

• Zealand Pharma Enters Into Expanded Collaboration Agreement With Wyeth Pharmaceuticals (New Jersey)

  3/4/2005

• ConjuChem

  4/19/2004